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creativecommons.org/licenses/by-nc-nd/Abstract Background: Analyses of phase III trials showed that denosumab was superior to
zoledronic acid (ZA) in preventing skeletal-related events (SREs) irrespective of age, history of
SREs, or baseline pain status. This analysis assessed the risk of SREs across additional base-
line characteristics.
Patients and Methods: Patients (NZ 5543) from three phase III trials who had breast cancer,
prostate cancer, or other solid tumours and one or more bone metastasis were included. Su-
periority of denosumab versus ZA in reducing risk of first SRE and first and subsequent SREs
was assessed in subgroups defined by the Eastern Cooperative Oncology Group performancencology, Pennsylvania State University, Milton S. Hershey Medical Center, 500 University Drive, Suite
1 717 531 8678.
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A. Lipton et al. / European Journal of Cancer 53 (2016) 75e8376status (ECOG PS), bone metastasis location, bone metastasis number, visceral metastasis pres-
ence/absence, and urinary N-telopeptide (uNTx) level using Cox proportional hazards and
AndersoneGill models. Subgroups except bone metastasis location were also assessed for each
solid tumour type.
Results: Compared with ZA, denosumab significantly reduced the risk of first SRE
across all subgroups (hazard ratio [HR] ranges: ECOG PS, 0.79e0.84; bone metastasis loca-
tion, 0.78e0.83; bone metastasis number, 0.78e0.84; visceral metastasis presence/absence,
0.80e0.82; uNTx level, 0.73e0.86) and reduced the risk of first and subsequent SREs in all
subgroups (HR ranges: ECOG PS, 0.76e0.83; bone metastasis location, 0.78e0.84; bone
metastasis number, 0.79e0.81; visceral metastasis presence/absence, 0.79e0.81; uNTx level,
0.74e0.83). Similar results were observed in subgroups across tumour types.
Conclusion: Denosumab was superior to ZA in preventing SREs in patients with bone metas-
tases from advanced cancer, regardless of ECOG PS, bone metastasis number, baseline
visceral metastasis presence/absence, and uNTx level.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with bone metastases are at increased risk for
skeletal complications, including pathologic fracture,
spinal cord compression, and radiation or surgery to the
bone, collectively termed skeletal-related events (SREs)
[1]. SREs are associated with not only substantial
morbidity but also greater mortality, increased pain,
decreased quality of life, and increased treatment costs
[2e6].
Bone-targeting agents have been shown to reduce
SREs associated with bone metastases/lesions in patients
with advanced solid tumours or multiple myeloma
[6e11]. Denosumab is a fully human monoclonal anti-
body against RANK ligand (RANKL), an important
regulator of osteoclast-mediated bone resorption [12]. In
a prespecified combined analysis of three identically
designed phase III randomised clinical trials,
denosumab was superior to zoledronic acid (ZA) in
reducing the risk of first on-study SRE (17% risk
reduction; P < 0.001) and the risk of first and subse-
quent on-study SREs (18% risk reduction; P < 0.001) in
patients with bone metastases/lesions from breast can-
cer, prostate cancer, or other solid tumours and multiple
myeloma [13].
Previous publications have reported a variety of po-
tential risk factors for the occurrence of SREs in pa-
tients with bone metastases from lung, breast, or
prostate cancer, including history of SREs, Eastern
Cooperative Oncology Group performance status
(ECOG PS), extent of bone disease, pain status, and
urinary N-telopeptide (uNTx) level, a frequently used
bone turnover marker [14e19]. However, it is unknown
whether such risk factors could be used to identify pa-
tients most likely to benefit from treatment with bone-
targeted agents. Previous analyses of the phase III tri-
als of denosumab described above have shown that
denosumab was superior to ZA in preventing SREsregardless of patient age, SRE history, or baseline pain
status [13]. In the current combined analysis of these
three trials, we assessed the ability of denosumab every 4
weeks (Q4W) versus ZA Q4W to reduce the risk of
SREs across a larger group of baseline characteristics,
including ECOG PS, location of bone metastases,
number of bone metastases, presence or absence of
visceral metastases, and uNTx level, both in the overall
population and by tumour type. These characteristics
are typically considered by clinicians when evaluating
patients for bone-targeted therapy.
2. Materials and methods
2.1. Patients
This was a post hoc analysis of three identically
designed, double-blind, double-dummy phase III trials
in patients with breast cancer (NCT00321464) [8],
prostate cancer (NCT00321620) [9], or other solid tu-
mours (NCT00330759) [10]. Patients with multiple
myeloma were excluded (ZA, n Z 93; denosumab,
n Z 87; Fig. 1). Eligible patients had radiographic evi-
dence of at least one bone metastasis, adequate organ
function, and ECOG PS 2. Exclusion criteria included
creatinine clearance <30 ml/min (per ZA prescribing
information) [20], life expectancy <6 months, and oral
or intravenous bisphosphonate for treatment of bone
metastases. Patients provided written informed consent;
the trial protocols were approved by each site’s ethics
committee.
2.2. Trial design and treatment
Patients were randomised to receive subcutaneous
denosumab 120 mg or intravenous ZA 4 mg Q4W (or
equivalent creatinine clearanceeadjusted dose of ZA per
the prescribing information). Randomisation was
A. Lipton et al. / European Journal of Cancer 53 (2016) 75e83 77stratified by prior SRE and other factors specific to the
cancer type (breast cancer, prostate cancer, or other
solid tumours and multiple myeloma) in each trial. The
other factors were prior oral bisphosphonate use, cur-
rent chemotherapy, and geographic region in the breast
cancer trial [8]; prostate-specific antigen and chemo-
therapy for prostate cancer within 6 weeks before ran-
domisation in the prostate cancer trial [9]; and tumour
type, previous SRE, and systemic anticancer therapy at
enrolment in the trial for other solid tumours and
multiple myeloma [10]. All patients, investigators, and
trial sponsor personnel remained blinded to treatment.
2.3. Statistical analysis
The primary end-point of the phase III trials was time to
first on-study SRE (assessed as noninferiority or supe-
riority) [8e10]. SREs were defined as radiation therapy
to bone (including radioisotopes), pathologic fracture
(excluding trauma), surgery to bone, or spinal cord
compression. Time to first and subsequent on-study
SREs (assessed for superiority) was a secondary end-
point. Radiologic assessments included skeletal surveys
(i.e. radiographs) performed every 12 weeks and un-
scheduled radiographic examinations performed for
symptoms. All radiographic evidence was assessed by
blinded centralised image review. For each subgroup
defined by the baseline characteristics investigated, time
to first on-study SRE was assessed using a Cox pro-
portional hazards model with treatment as a covariate
and stratified by study and the randomisation stratifi-
cation factors for the analysis in the overall population,
as well as the analysis by tumour type. Similarly, time to
first and subsequent on-study SREs was assessed using
an AndersoneGill model with treatment as a covariate
and stratified by study and the randomisationPatients randomised to receive denosumab 
(n=1026)
Patients randomised to receive zoledronic acid  
(n=1020)
Patients with breast cancer (n=2046) Patients with prostate cance
Patients randomised to rece
(n=950)
Patients randomised to rece
(n=951)
Patients included in the analysis 
Patients randomised to receiv
Patients randomised to receiv
Fig. 1. Flowchart of patients included in the overall population analysis
characteristic subgroups by solid tumour type. ‘*’, Indicates that patie
n Z 87) were excluded from this analysis.stratification factors. Subgroups by treatment in-
teractions were tested for each of the baseline charac-
teristics in the models described above in the overall
group by adding the subgroup and subgroup by treat-
ment interaction in the model. All statistical compari-
sons were two-sided with a 0.05 level of significance. P
values were not adjusted for multiplicity.
2.4. Analysis by baseline characteristics
The analysis of baseline characteristic subgroups
included all trial patients except those with multiple
myeloma (i.e. those with breast cancer, prostate cancer,
or other solid tumours; Fig. 1). In the overall pooled
analysis population, the superiority of denosumab
versus ZA in reducing the risk of first on-study SRE and
first and subsequent on-study SREs was assessed in
patient subgroups defined by ECOG PS (0 versus 1),
location of bone metastases per central imaging review
(axial skeleton only [skull, vertebral column, ribs, and
sternum] versus appendicular skeleton only [limbs and
thoracic and pelvic girdles] versus both axial and
appendicular skeleton), number of bone metastases per
central imaging review (<2 versus 2), presence or
absence of visceral metastases (yes versus no), and uNTx
level (43.7 nmol/mmol [the median uNTx level
observed across the three phase III trials] versus
<43.7 nmol/mmol).
Among patients with each of the solid tumour types
reported in the original trials except multiple myeloma
(breast cancer, prostate cancer, or other solid tumours),
the superiority of denosumab compared with ZA in
reducing the risk of first on-study SRE and first and
subsequent on-study SREs was assessed in subgroups
based on ECOG PS (0 versus 1), number of bone
metastases (<2 versus 2), presence or absence ofr (n=1901)
ive denosumab 
ive zoledronic acid 
Patients with other solid tumours* (n=1596) 
Patients randomised to receive denosumab 
(n=799)
Patients randomised to receive zoledronic acid
(n=797)
(n=5543)
e denosumab (n=2775)
e zoledronic acid (n=2768)
of baseline characteristic subgroups and in the analysis of baseline
nts with multiple myeloma (zoledronic acid, n Z 93; denosumab,
Table 1
Patient demographics and baseline characteristics.
Characteristic Zoledronic acid
(n Z 2768)
Denosumab
(n Z 2775)
Tumour type, n (%)
Breast 1020 (37) 1026 (37)
Prostate 951 (34) 950 (34)
Other solid tumours 797 (29) 799 (29)
ECOG performance status,a n (%)
0 1120 (41) 1141 (41)
1 1640 (59) 1631 (59)
Location of bone metastases,b,c n (%)
Axial only 672 (24) 706 (25)
Appendicular only 345 (13) 387 (14)
Axial and appendicular 833 (30) 804 (29)
Number of bone metastases, n (%)
<2 1696 (61) 1689 (61)
2 1072 (39) 1086 (39)
Presence or absence of visceral metastasis, n (%)
Yes 1152 (42) 1185 (43)
No 1616 (58) 1590 (57)
Median uNTx level,d n (%)
43.7 nmol/mmol 1222 (44) 1254 (45)
<43.7 nmol/mmol 1246 (45) 1229 (44)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; uNTx,
urinary N-telopeptide.
a n Z 2760 for zoledronic acid; n Z 2772 for denosumab.
b n Z 1850 for zoledronic acid; n Z 1897 for denosumab.
c Per central imaging review.
d n Z 2468 for zoledronic acid; n Z 2483 for denosumab.
A. Lipton et al. / European Journal of Cancer 53 (2016) 75e8378visceral metastases (yes versus no), and uNTx level
(43.7 nmol/mmol [median] or <43.7 nmol/mmol).
When baseline characteristics were assessed by solid
tumour type, there were insufficient data for the
assessment of location of bone metastases.
3. Results
3.1. Patients
Of the 5732 patients enrolled in the three trials between
April 2006 and October 2009, 5543 were included in the
efficacy analysis (Fig. 1). Patient disposition for the
three combined trials has been previously published [13].
Patient demographics and baseline disease characteris-
tics were similar between treatment groups (Table 1).
3.2. Assessment of efficacy across baseline characteristics
in overall population
The percentages of risk reduction for first on-study SRE
and for first and subsequent on-study SREs with
denosumab compared with ZA in the overall population
(breast cancer, prostate cancer, or other solid tumours)
are shown in Figs. 2 and 3, respectively. For time to first
on-study SRE and time to first and subsequent on-study
SREs, none of the subgroup by treatment interaction
tests were statistically significant, indicating the consis-
tency of treatment effects across the subgroups. Treat-
ment with denosumab significantly reduced the risk of
first on-study SRE compared with ZA across all baseline
subgroups, including ECOGPS (0 versus1) at baseline,
location of bone metastases (axial versus appendicular
versus both), number of bone metastases (<2 versus2),
presence or absence of visceral metastasis (yes versus no),
and uNTx level (43.7 nmol/mmol [median] or
<43.7 nmol/mmol) (Fig. 2). Similarly, treatment with
denosumab significantly reduced the risk of first and
subsequent on-study SREs compared with ZA across all
the baseline subgroups, with the exception of the
appendicular skeleton subgroup (the smallest subgroup
assessed), which failed to meet nominal statistical sig-
nificance (PZ 0.072) despite having a point estimate that
was similar to the other metastasis locations (Fig. 3).
Median time to first on-study SRE was longer with
denosumab compared with ZA across all baseline sub-
groups (Supplemental Table 1).
3.3. Assessment of efficacy across baseline characteristics
by solid tumour type
Further analysis of four baseline characteristic sub-
groups (ECOG PS, number of bone metastases, pres-
ence or absence of visceral metastasis, and uNTx level)
showed a reduced risk of first on-study SRE with
denosumab versus ZA among patients with each solid
tumour type (breast cancer, prostate cancer, and othersolid tumours). Sample size was limited for some sub-
groups in the analysis by tumour type, which may limit
interpretation of these data (Fig. 4). Similar outcomes
were observed for first and subsequent SREs (Fig. 5).
Consistent with the assessment in the overall popula-
tion, none of the subgroup treatment interaction tests by
tumour type were statistically significant.
4. Discussion
Several risk factors for the occurrence of SREs have been
identified in patients with bone metastases from lung,
breast, or prostate cancer, including history of SREs,
ECOG PS, extent of bone disease, pain status, and uNTx
level [14e19]. In this combined analysis of three identi-
cally designed trials, we assessed whether denosumab
Q4W was superior to ZA Q4W in reducing the risk of
SREs across patient subgroups by the baseline charac-
teristics that have been identified as potential risk factors
for SREs and that are among those commonly consid-
ered by clinicians when considering bone-targeted ther-
apy.We found that denosumab Q4Wwas superior to ZA
Q4W in reducing the risk of first on-study SRE and first
and subsequent on-study SREs, irrespective of key pa-
tient baseline characteristics such as ECOG PS, number
of bone metastases, presence or absence of visceral me-
tastases, and baseline uNTx level. These results were
consistent across solid tumour types (breast cancer,
prostate cancer, and other solid tumours).
HR* (95% CI) P Value
0.83 (0.69–1.00) 0.0443
0.78 (0.61–0.99) 0.0428
0.81 (0.69–0.95) 0.0104
0.80 (0.69–0.93) 0.0026
0.82 (0.73–0.93) 0.0011
0.86 (0.75–0.98) 0.0225
0.73 (0.64–0.85) <0.0001
0.84 (0.74–0.94) 0.0033
0.78 (0.68–0.90) 0.0005
0.79 (0.69–0.92) 0.0020
0.84 (0.74–0.94) 0.0025
0.82 (0.75–0.89) <0.0001
0.50 0.75 1.00 1.25
Zoledronic Acid Denosumab
n/N n/N
260/672 226/706
144/345 134/387
340/833 278/804
403/1152 351/1185
632/1616 539/1590
474/1222 438/1254
458/1246 357/1229
599/1696 520/1689
436/1072 370/1086
396/1120 341/1141
635/1640 547/1631
1035/2768 890/2775Overall
≥1
0
ECOG performance status
≥2
<2
Number of bone metastases
<43.7 nmol/mmol
≥43.7 nmol/mmol
uNTx level
No
Yes
Presence or absence of visceral metastasis
Axial and appendicular
Appendicular only
Axial only
Location of bone metastases
Hazard Ratio
Favors denosumab Favors zoledronic acid
Fig. 2. Risk of first on-study SRE by baseline characteristic subgroups in the overall analysis population. ECOG, Eastern Cooperative
Oncology Group; HR, hazard ratio; SRE, skeletal-related event; uNTx, urinary N-telopeptide; n, number of patients with events; N,
number of randomised patients. ‘*’, Based on a Cox proportional hazards model with treatment groups as the independent variable
stratified by the randomisation stratification factors. ‘y’, Median Z 43.7 nmol/mmol.
A. Lipton et al. / European Journal of Cancer 53 (2016) 75e83 79Consistent with the results of this analysis, Lipton
et al [13] found that denosumab Q4W reduced the risk
of SRE compared with ZA Q4W in patients with a
previous SRE (16% risk reduction; P Z 0.01), in those
without a previous SRE (18% risk reduction;
P < 0.001), and in patients <65 and 65 years of age
(18% risk reduction for both groups; P < 0.01). In0.50 0.75 1.00
Overall
≥1
0
ECOG performance status
≥2
<2
Number of bone metastases
<43.7 nmol/mmol
≥43.7 nmol/mmol
uNTx level
No
Yes
Presence or absence of visceral metastasis
Axial and appendicular
Appendicular only
Axial only
Location of bone metastases
Rate Ratio
Favors denosumab Fa
Fig. 3. Risk of first and subsequent on-study SREs by baseline characte
Cooperative Oncology Group; RR, rate ratio; SRE, skeletal-related ev
events; N is the number of randomised patients. ‘*’, Based on an A
factors. ‘y’, Median Z 43.7 nmol/mmol.another analysis of these trials, von Moos et al [21]
reported that denosumab Q4W significantly delayed
time to first SRE compared with ZA Q4W in patients
with no/mild baseline pain at trial entry (16% risk
reduction; P Z 0.01) and in those with moderate/se-
vere pain at trial entry (17% risk reduction;
P Z 0.003). The risk reductions achieved in theseRR* (95% CI) P Value
0.84 (0.71–0.99) 0.0422
0.81 (0.65–1.02) 0.0715
0.78 (0.67–0.91) 0.0018
0.79 (0.69–0.91) 0.0007
0.81 (0.72–0.91) 0.0003
0.83 (0.73–0.94) 0.0035
0.74 (0.65–0.85) <0.0001
0.81 (0.72–0.91) 0.0002
0.79 (0.69–0.91) 0.0009
0.76 (0.66–0.88) 0.0002
0.83 (0.74–0.92) 0.0007
0.81 (0.74–0.88) <0.0001
1.25
Zoledronic Acid Denosumab
n/N n/N
363/672 316/706
205/345 200/387
577/833 441/804
576/1152 483/1185
990/1616 811/1590
755/1222 664/1254
658/1246 492/1229
867/1696 717/1689
699/1072 577/1086
612/1120 498/1141
949/1640 794/1631
1566/2768 1294/2775
vors zoledronic acid
ristic subgroups in the overall analysis population. ECOG, Eastern
ent; uNTx, urinary N-telopeptide; n, the number of patients with
nderseneGill model stratified by the randomisation stratification
HR* (95% CI) P Value
0.80 (0.64–1.00) 0.0475
0.85 (0.69–1.04) 0.1148
0.85 (0.68–1.06) 0.1415
0.75 (0.58–0.95) 0.0188
0.86 (0.70–1.05) 0.1428
0.78 (0.62–0.98) 0.0357
0.88 (0.70–1.12) 0.3127
0.78 (0.64–0.95) 0.0122
0.82 (0.71–0.95) 0.0101
Zoledronic Acid Denosumab
n/N n/N
170/525 149/552
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182/442 153/438
148/447 120/470
205/627 177/631
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227/528 181/520
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≥1
0
ECOG performance status
≥2
<2
Number of bone metastases
<43.7 nmol/mmol
≥43.7 nmol/mmol
uNTx level
No
Yes
Presence or absence of visceral metastasis
0.85 (0.60–1.19) 0.3302
0.82 (0.70–0.97) 0.0182
0.86 (0.70–1.05) 0.1363
0.72 (0.57–0.92) 0.0074
0.87 (0.70–1.08) 0.2001
0.76 (0.62–0.94) 0.0096
0.77 (0.62–0.96) 0.0208
0.87 (0.71–1.06) 0.1739
0.82 (0.71–0.95) 0.0085
80/181 64/161
306/770 277/789
193/493 199/536
168/401 124/372
191/484 169/470
195/467 172/480
181/426 147/418
205/525 194/532
386/951 341/950
Overall
≥1
0
ECOG performance status
≥2
<2
Number of bone metastases
<43.7 nmol/mmol
≥43.7 nmol/mmol
uNTx level
No
Yes
Presence or absence of visceral metastasis
0.78 (0.62–0.99) 0.0371
0.79 (0.61–1.04) 0.0944
0.87 (0.65–1.17) 0.3642
0.73 (0.57–0.94) 0.0156
0.78 (0.64–0.96) 0.0200
0.83 (0.59–1.18) 0.3043
0.68 (0.48–0.96) 0.0300
0.87 (0.71–1.07) 0.1768
0.80 (0.67–0.96) 0.0134
153/446 138/472
124/351 96/327
99/287 86/280
142/398 113/387
203/585 174/588
74/212 60/211
72/206 62/219
203/587 172/579
277/797 234/799Overall
≥1
0
ECOG performance status
≥2
<2
Number of bone metastases
<43.7 nmol/mmol
≥43.7 nmol/mmol
uNTx level
No
Yes
Presence or absence of visceral metastasis
Breast cancer
Prostate cancer
Other solid tumors
Hazard Ratio
Favors denosumab Favors zoledronic acid
0.50 0.75 1.00 1.25 1.50 1.75
Fig. 4. Risk of first on-study SRE by baseline characteristic subgroups in patients with breast cancer, prostate cancer, or other solid
tumours. ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; SRE, skeletal-related event; uNTx, urinary N-telopeptide; n,
the number of patients with events; N is the number of randomised patients. ‘*’, Based on a Cox proportional hazards model with
treatment groups as the independent variable stratified by the randomisation stratification factors. ‘y’, Median Z 43.7 nmol/mmol.
A. Lipton et al. / European Journal of Cancer 53 (2016) 75e8380subgroups were of a similar magnitude to those in the
current subgroup analysis. In the proof-of-concept
randomised phase II trial in patients with bone me-
tastases/lesions from breast cancer, prostate cancer, or
other neoplasms and multiple myeloma who had
elevated uNTx levels and prior exposure to intravenous
bisphosphonates, treatment with denosumab resulted
in a greater reduction in osteolysis and a lower inci-
dence of on-study SREs compared with intravenous
bisphosphonate [22e24].
A strength of this study was its use of a patient-level
combined analysis approach, which allowed for the
evaluation of clinical characteristics. Our results suggestthat in all subgroups of patients, denosumab provided
superior protection against the development of SREs,
confirming the importance of the RANK/RANKL
pathway in SRE pathophysiology in patients with bone
metastases from solid tumours. Previous analyses have
also shown a greater treatment effect of denosumab
versus ZA in preventing SREs regardless of prior SREs
[13] and increased baseline pain [21]. As with previous
analyses assessing baseline characteristics and SRE risk,
this study was limited by its post hoc design and the
analyses of multiple end-points by multiple subgroup
variables that were not corrected for in the statistical
design. In addition, small sample sizes in several
RR* (95% CI) P Value
0.78 (0.63–0.97) 0.0254
0.77 (0.63–0.94) 0.0111
0.81 (0.66–1.00) 0.0467
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303/467 253/480
276/426 222/418
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0.89 (0.70–1.15) 0.3744
0.94 (0.72–1.23) 0.6474
0.73 (0.58–0.92) 0.0084
0.81 (0.67–0.98) 0.0309
0.92 (0.67–1.25) 0.5807
0.78 (0.57–1.06) 0.1119
0.88 (0.73–1.06) 0.1857
0.85 (0.72–1.00) 0.0447
210/446 184/472
164/351 142/327
133/287 123/280
196/398 146/387
278/585 236/588
96/212 90/211
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≥43.7 nmol/mmol
uNTx level
No
Yes
Presence or absence of visceral metastasis
Prostate cancer
Other solid tumors
Rate Ratio
Favors denosumab Favors zoledronic acid
0.50 0.75 1.00 1.25 1.50 1.75
Fig. 5. Risk of first and subsequent on-study SREs by baseline characteristic subgroups in patients with breast cancer, prostate cancer, or
other solid tumours. ECOG, Eastern Cooperative Oncology Group; RR, rate ratio; SRE, skeletal-related event; uNTx, urinary N-telo-
peptide; n, number of patients with events; N, number of randomised patients. ‘*’, Based on an AnderseneGill model stratified by the
randomisation stratification factors. ‘y’, MedianZ43.7 nmol/mmol.
A. Lipton et al. / European Journal of Cancer 53 (2016) 75e83 81subgroups may limit interpretation of subgroup analyses
by specific tumour types.
In conclusion, this analysis showed that denosumab
Q4W is superior to ZA Q4W in preventing SREs in all
patients with metastatic bone disease, regardless of the
baseline characteristics of ECOG PS, number of bone
metastases, presence or absence of visceral metastases,
and uNTx level.
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